Latest news with #BioconLtd
Time of India
3 days ago
- Business
- Time of India
Biocon Q1 net profit falls 95% to Rs 31 crore
Representative image NEW DELHI: Biocon on Thursday reported a 95 per cent decrease in its consolidated net profit at Rs 31 crore in the June quarter. The Bengaluru-based firm posted a net profit of Rs 660 crore in the April-June quarter of the last fiscal. Total revenue declined to Rs 4,022 crore in the June quarter as against Rs 4,567 crore in the year-ago period, Biocon Ltd said in a statement. "Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics," Kiran Mazumdar-Shaw, Chairperson, Biocon Group, stated. Operating revenue rose 15 per cent YoY to Rs 3,942 crore, with EBITDA up 19 per cent on a like-for-like basis, demonstrating operating leverage and the robustness of businesses, she added. "The recent QIP has strengthened our balance sheet and enabled us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities," Mazumdar-Shaw said. With execution momentum across all businesses and expanded capacity through acquisitions in the US by Syngene and Biocon Generics, the company is well-positioned to drive long-term value creation in FY26 and beyond, she added. Stay informed with the latest business news, updates on bank holidays and public holidays .
Business Standard
5 days ago
- Business
- Business Standard
Quick Wrap: Nifty Pharma Index declines 0.83%
Nifty Pharma index ended down 0.83% at 21970.15 today. The index is down 2.00% over last one month. Among the constituents, Biocon Ltd shed 2.63%, Abbott India Ltd dropped 2.18% and Divis Laboratories Ltd slipped 1.24%. The Nifty Pharma index is up 2.00% over last one year compared to the 2.47% surge in benchmark Nifty 50 index. In other indices, Nifty FMCG index is down 0.72% and Nifty IT index has dropped 0.48% on the day. In broad markets, the Nifty 50 has dropped 0.30% to close at 24649.55 while the SENSEX has dropped 0.38% to close at 80710.25 today.
Business Standard
5 days ago
- Business
- Business Standard
Biocon Ltd slips for fifth straight session
Biocon Ltd is quoting at Rs 372.85, down 2.5% on the day as on 13:19 IST on the NSE. The stock jumped 11.46% in last one year as compared to a 2.63% rally in NIFTY and a 1.59% spurt in the Nifty Pharma index. Biocon Ltd dropped for a fifth straight session today. The stock is quoting at Rs 372.85, down 2.5% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 24624.55. The Sensex is at 80672.42, down 0.43%.Biocon Ltd has added around 0.2% in last one Nifty Pharma index of which Biocon Ltd is a constituent, has eased around 2.06% in last one month and is currently quoting at 22153.8, down 1.12% on the day. The volume in the stock stood at 18.27 lakh shares today, compared to the daily average of 47.7 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 373.3, down 2.87% on the day. Biocon Ltd jumped 11.46% in last one year as compared to a 2.63% rally in NIFTY and a 1.59% spurt in the Nifty Pharma index. The PE of the stock is 0 based on TTM earnings ending March 25.
Economic Times
30-07-2025
- Business
- Economic Times
Biocon Biologics gets USFDA nod for diabetes medication
Agencies Representative image. New Delhi: Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication. The company, a unit of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. The medication will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use, Biocon said in a statement. The approval expands Biocon Biologics' biosimilar insulin portfolio, which also includes the interchangeable biosimilar, Semglee (Insulin Glargine-yfgn Injection). An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP). Kirsty has been available in Europe and Canada since 2022. As per the company, there are 38.4 million people with diabetes in the US, around 11.6 per cent of the total population, with nearly a quarter of them being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic, it added. According to IQVIA, sales of Insulin Aspart in the US stood around USD 1.9 billion in 2024. Shares of Biocon were trading 1.44 per cent up at Rs 395.80 apiece on the BSE.
Mint
18-07-2025
- Business
- Mint
Stock market today: 143 stocks hit 52-week highs, 45 stocks at 52-week low as Nifty 50, Sensex end in red
Stock market today: On Friday, 143 stocks hit their 52-week high, including Anand Rathi Wealth Ltd, Biocon Ltd, Dalmia Bharat Ltd, Gujarat Mineral Development Corporation Ltd, HDFC Asset Management Company Ltd, JK Cement Ltd, Krishna Institute of Medical Sciences Ltd, Nuvoco Vistas Corporation Ltd, Piramal Enterprises Ltd, and RBL Bank Ltd. In contrast, 45 stocks touched 52-week lows, with notable mentions like Bharat Global Developers Ltd, HDB Financial Services Ltd, Mirae Asset Nifty India Internet ETF, Jindal Worldwide Ltd, Network People Services Technologies Ltd, and Sukhjit Starch & Chemicals Ltd. Today, the Indian stock market concluded on a negative note, with the Nifty 50 closing at approximately 24,968, reflecting a decline of around 0.57% (143 points), falling further beneath the crucial 25,000 mark following a widespread sell-off. The Sensex also fell by about 501 points, finishing close to 81,757. Based on insights from experts, the unfavorable market close was mainly influenced by unsatisfactory earnings reports, particularly from Axis Bank, whose performance in Q1FY26 raised concerns among investors and led to a significant drop in financial stocks such as HDFC Bank and Kotak Mahindra Bank.
